Key facts
- Notable investors include Cowin Capital, TusStar Incubator, Qianhai VC Incubator, Shenzhen Bangqin Venture Capital Fund Management, Shenzhen HTI Group — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for NewDEL Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for NewDEL Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NewDEL Biotech
Developer of innovative drugs designed for tumors. The company offers DNA Encoded Library technology to significantly improve the success rate of drugs, thereby enabling tumor patients to have next-generation alternative medicines.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2021
- Website
- newdel.com.cn/
- Ownership
- Privately Held (backing)
NewDEL Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NewDEL Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NewDEL Biotech in its N-PORT filings yet. We sweep new filings monthly.